Emma Walmsley, GlaxoSmithKline CEO (Fang Zhe/Xinhua/Alamy Live News)

GSK's con­sumer health spin­off Ha­le­on preps launch with $12B+ in debt

GSK’s con­sumer health spin­off Ha­le­on will make its big de­but in just over a week — but with some se­ri­ous debt in tow, ac­cord­ing to the com­pa­ny.

When it lists on the Lon­don Stock Ex­change on Ju­ly 18, Ha­le­on will have about £10.3 bil­lion (more than $12 bil­lion) in debt on the bal­ance sheet, GSK con­firmed on Wednes­day. That’s around four times the spin­off’s es­ti­mat­ed earn­ings for the year, ac­cord­ing to the UK’s This is Mon­ey, which first re­port­ed the news.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.